Pharmaceuticals Policy and LawISSN: 1389-2827
Volume 13; 4 issues
Institutional subscription (print and online) for 2011: €368 / US$505 (including postage and handling)
Click on the subscribe button for more options, including personal subscription prices.
Status Report: Last issue (volume 12:3-4) online on 19 January 2011
Next issue (volume 13:1) scheduled for June 2011
Aims and Scope
Submission of Manuscripts
Download flyer for this journal
Editor-in-ChiefProf. José Luis Valverde
Chair Jean Monnet, EU: 'Europe of the Health'
University of Granada
Faculty of Pharmacy
Campus de la Cartuja sn
Tel.: +34 958 24 38 98
Fax:+34 958 24 89 08
instructions to authors.
The specificity of medicinal products conditions their legal status. Legislation regulating other goods cannot be applied to them. To begin with, they are the result of scientific and technical innovation. Research policies determine their progress. The pharmaceutical industry is, by nature, multinational. But, next to these global trends, different traditions still remain at a national level. Within the EU, barriers to free trade in medicinal products still remain despite more than thirty years of harmonisation. The social dimension of medicinal products is complex and very significant in the preoccupations of our societies. Patenting is essential but not sufficient. The life-cycle of medicinal products is protected by professional responsibility, required in the general concept of health safety. It is important to remember their ethical dimension, including research and innovation in new fields such as genetic manipulation and biotechnology, which requires social consent to preserve human dignity and fundamental rights.
Abstracted inEBSCO database